| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 6.2% stake in SOLENO THERAPEUTICS, INC. |
| 10/03/2023 |
4
| Fairmount Funds Management LLC (10% Owner) has filed a Form 4 on Dianthus Therapeutics, Inc. /DE/|
Txns:
| Bought 24,670 shares
@ $13.63, valued at
$336.3k
|
|
| 09/28/2023 |
4
| Fairmount Funds Management LLC (10% Owner) has filed a Form 4 on Dianthus Therapeutics, Inc. /DE/|
Txns:
| Bought 30,000 shares
@ $13.15, valued at
$394.5k
|
|
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/10/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 6.1% stake in Kiniksa Pharmaceuticals, Ltd. |
| 07/21/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 07/17/2023 |
4
| Fairmount Funds Management LLC (Director) has filed a Form 4 on Apogee Therapeutics, Inc.|
Txns:
| Bought 55,913 shares
@ $17, valued at
$950.5k
Bought 1,992,734 shares
@ $17, valued at
$33.9M
Bought 892,529 shares
@ $17, valued at
$15.2M
Granted 47,758 options to buy
@ $17, valued at
$811.9k
|
|
| 07/13/2023 |
3
| Fairmount Funds Management LLC (Director) has filed a Form 3 on Apogee Therapeutics, Inc. |
| 07/07/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 5% stake in AXSOME THERAPEUTICS, INC. |
| 06/30/2023 |
3
| Fairmount Funds Management LLC (10% Owner) has filed a Form 3 on Aeglea BioTherapeutics, Inc. |
| 06/30/2023 |
SC 13D
| Fairmount Funds Management LLC reports a 20% stake in AEGLEA BIOTHERAPEUTICS, INC. |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 7.7% stake in ANNEXON, INC. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 4.6% stake in AXSOME THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 6.9% stake in Astria Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 0% stake in Olema Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 5.5% stake in NUVALENT, INC. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 9.9% stake in Terns Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 9.9% stake in TREVI THERAPEUTICS, INC. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/09/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/09/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/25/2022 |
SC 13G
| Fairmount Funds Management LLC reports a 5.4% stake in AXSOME THERAPEUTICS, INC. |
| 08/25/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/19/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 06/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/21/2022 |
SC 13G
| Fairmount Funds Management LLC reports a 9.9% stake in TREVI THERAPEUTICS, INC. |
| 04/21/2022 |
SC 13G
| Fairmount Funds Management LLC reports a 6.7% stake in ANNEXON, INC. |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
|